MOBERG DERMA SIGNS AGREEMENT FOR NALOX™/ EMTRIX® IN IRAN

Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Ana
Darou P.J.S. for Nalox™/Emtrix® – for discolored and damaged nails caused by
nail fungus (onychomycosis) or nail psoriasis. Under the agreement Ana Darou is
granted exclusive rights to market and sell Nalox™/Emtrix® in Iran. Moberg Derma
assumes production and supply responsibility.
“The agreement is part of our international commercialization of Nalox™/Emtrix®.
We are looking forward to make the product available to the patients in Iran
through the cooperation with Ana Darou”, says Peter Wolpert, CEO and founder of
Moberg Derma.

About Nalox™ and nail diseases
Nalox™ is a topical treatment used to treat nail disease. Launched in the Nordic
region in autumn 2010, it quickly became market leader. Nalox™ is a prescription
free, over-the-counter product sold under the name Emtrix® in certain markets
and under the name Kerasal® Nail in the U.S. Safety and efficacy have been
demonstrated in several clinical studies including more than 600 patients.
Nalox™ has a unique and rapid mechanism of action which brings visible
improvements within 2-4 weeks of treatment. Nail fungus is the most common nail
disease and afflicts approximately 10% of the general population and increasing
with age. The estimated global market potential exceeds USD 1 billion. The
untapped potential is significant since many patients remain untreated. It is
generally recognized that there is a need for new efficacious and safe topical
treatments.

About this information
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication on at 8:30 am (CET) on June 25th,
2012.
For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical
pharmaceuticals for the treatment of common disorders through the use of
innovative drug delivery. The company’s products are based on proven compounds,
which reduce time to market, development costs and risk. Moberg Derma’s first
product Nalox™/Emtrix®- for nail disorders - became the Nordic market leader
directly after launch in autumn 2010 and international launch is ongoing. The
portfolio includes approved and launched products to projects in the preclinical
and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of
the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergderma.se